Corning will highlight its enhanced 3D cell culture portfolio, including Corning® Elplasia® plates featuring microcavity technology for spheroid production, and Matrigel® matrix for organoid culture.
In addition, the company will exhibit the Corning® MicroDEN® Perfusion-based Dendritic Cell Culture Platform system, an automated system that streamlines dendritic cell generation for cell and gene therapy applications. Notably, Corning Elplasia plates have been nominated for the Select Science Scientists' Choice Awards for Best New Drug Discovery & Development Product of 2019.
Corning experts will be onsite to demonstrate how these tools address advancements in 3D cell culture and cell therapy research. Applications for these tools include drug screening, cancer and tumor biology, stem cell biology, 3D tissue engineering, immunology, and immuno-oncology.
Corning Life Sciences leadership - including John M. Tobin, newly appointed vice president and general manager; and Dr. Keith Olson, vice president, Business Operations and Technology - will be available to share insights at booth #1318. Please visit Corning.com/SLAS2020 for more information and updates to the technical program.
Corning and its customers will also offer several presentations and posters during SLAS including:
Presentations and Tutorials
Sunday, Jan. 26, 2020
Short Course: Set-up and Validation of 3D Primary, Stem Cell, and Immortalized Cultures for Downstream Microplate Reader and Imaging Applications
Presented by: Austin Mogen, field applications scientist, Corning Life Sciences; and Joe Clayton, principal scientist, Biotek Instruments
8:30 a.m. - 12:30 p.m.
Room 14A in the San Diego Convention Center
Monday, Jan. 27, 2020
Solutions Spotlight: Unlocking the Potential of 3D Cell Culture
Presented by: Christopher Suarez, Ph.D., field applications manager, Corning Life Sciences
5:30 - 6 p.m.
Hall A, Spotlight Theater on the Exhibit Floor
Tuesday, Jan. 28, 2020
Tutorial: Advanced 3D Cell Culture Applications and Tips for Optimizing your 3D Assays
Presented by: Hilary Sherman, senior applications scientist, Corning Life Sciences; and Christopher Suarez, Ph.D., field applications manager, Corning Life Sciences
9:30 -10:15 a.m.
Convention Center Room 3
Tuesday, Jan. 28, 2020
Tutorial: Leveraging Patient-Derived Organoids for Therapeutic Impact
Presented by: Ralph Garippa, Ph.D., director, Gene Editing & Screening Core Facility, Memorial Sloan Kettering Cancer Center
12:30 -1:15 p.m.
Convention Center Room 3
Posters
Corning Life Sciences will present several posters, including:
Poster 1081-B: Corning® Matrigel® Matrix-3D plates for High-throughput 3D Assays
Presented by: Hilary Sherman, senior scientist, Corning Life Sciences
Monday January 27, 2020
5:00 PM - 6:00 PM
Poster 1079-E: Corning® Elplasia® Plates for Assays with Multiple Spheroids Per Well
Presented by: Hilary Sherman, senior scientist, Corning Life Sciences
Wednesday January 29, 2020
11:30 AM - 12:30 PM
Analysis of RNA Transcript Levels Reveals Upregulation of Hypoxia Markers for Pancreatic Cancer Cells Cultured in 3D
Presented by: Audrey Bergeron, application scientist, Corning Life Sciences
###
To learn more about how Corning is transforming and enabling the future of 3D cell culture with innovative technologies and workflow solutions, schedule a booth tour and a meeting with a member of the Corning team. Please contact:
Leanne Stone
(520) 490-0719
lstone@spectrumscience.com
Caution Concerning Forward-Looking Statements
This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning's financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effects of acquisitions, dispositions and other similar transactions by the Company, the effect of global business, financial, economic and political conditions; tariffs and import duties; currency fluctuations between the U.S. dollar and other currencies, primarily the Japanese yen, New Taiwan dollar, euro, Chinese yuan, and South Korean won; product demand and industry capacity; competitive products and pricing; availability and costs of critical components and materials; new product development and commercialization; order activity and demand from major customers; the amount and timing of our cash flows and earnings and other conditions, which may affect our ability to pay our quarterly dividend at the planned level or to repurchase shares at planned levels; possible disruption in commercial activities due to terrorist activity, cyber-attack, armed conflict, political or financial instability, natural disasters, or major health concerns; unanticipated disruption to equipment, facilities, IT systems or operations; effect of regulatory and legal developments; ability to pace capital spending to anticipated levels of customer demand; rate of technology change; ability to enforce patents and protect intellectual property and trade secrets; adverse litigation; product and components performance issues; retention of key personnel; customer ability, most notably in the Display Technologies segment, to maintain profitable operations and obtain financing to fund their ongoing operations and manufacturing expansions and pay their receivables when due; loss of significant customers; changes in tax laws and regulations including the Tax Cuts and Jobs Act of 2017; and the potential impact of legislation, government regulations, and other government action and investigations.
For a complete listing of risks and other factors, please reference the risk factors and forward-looking statements described in our annual reports on Form 10-K and quarterly reports on Form 10-Q. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.
Web Disclosure
In accordance with guidance provided by the SEC regarding the use of company websites and social media channels to disclose material information, Corning Incorporated ("Corning") wishes to notify investors, media, and other interested parties that it uses its website (http://www.corning.com/worldwide/en/about-us/news-events.html) to publish important information about the company, including information that may be deemed material to investors, or supplemental to information contained in this or other press releases. The list of websites and social media channels that the company uses may be updated on Corning's media and website from time to time. Corning encourages investors, media, and other interested parties to review the information Corning may publish through its website and social media channels as described above, in addition to the company's SEC filings, press releases, conference calls, and webcasts.
About Corning Incorporated
Corning (http://www.corning.com) is one of the world's leading innovators in materials science, with a more than 165-year track record of life-changing inventions. Corning applies its unparalleled expertise in glass science, ceramic science, and optical physics along with its deep manufacturing and engineering capabilities to develop category-defining products that transform industries and enhance people's lives. Corning succeeds through sustained investment in RD&E, a unique combination of material and process innovation, and deep, trust-based relationships with customers who are global leaders in their industries.
Corning's capabilities are versatile and synergistic, which allows the company to evolve to meet changing market needs, while also helping our customers capture new opportunities in dynamic industries. Today, Corning's markets include optical communications, mobile consumer electronics, display technology, automotive, and life sciences vessels. Corning's industry-leading products include damage-resistant cover glass for mobile devices; precision glass for advanced displays; optical fiber, wireless technologies, and connectivity solutions for state-of-the-art communications networks; trusted products to accelerate drug discovery and delivery; and clean-air technologies for cars and trucks.
Corning Media Contact:
Elizabeth Fryman
(978) 684-2659
frymane@corning.com